Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
StockNews.AI · 2 hours
AI Summary
Capricor Therapeutics announced that the FDA’s CTGTAC will review Deramiocel (CAP-1002) for Duchenne muscular dystrophy at a July 29, 2026 advisory meeting, with the BLA on track for an August 22, 2026 PDUFA date. Positive HOPE-3 results support a potential first-in-class approval path, reinforced by RMAT, orphan, and other designations that may streamline regulatory review.
Sentiment Rationale
Positive HOPE-3 data and imminent advisory/PDUFA dates create a meaningful near-term upside risk-reward for CAPR, typical of biotech regulatory catalysts.
Trading Thesis
Bullish CAPR on July 29 advisory and August 22 PDUFA with potential near-term upside within 1–3 months.
Market-Moving
- Advisory committee date set for July 29, 2026; outcome could move CAPR shares.
- HOPE-3 success increases probability of BLA approval and potential label expansion.
- PDUFA date August 22, 2026; near-term regulatory catalyst.
Key Facts
- FDA CTGTAC advisory meeting for Deramiocel on July 29, 2026; live stream planned.
- HOPE-3 success: primary endpoint PUL v2.0 and key cardiac endpoint LVEF achieved.
- RMAT, Orphan Drug, ATMP, and Rare Pediatric Disease designations may enable faster review.
- Deramiocel (CAP-1002) is allogeneic CDCs with potential first-in-class DMD therapy.
- PDUFA target date set for August 22, 2026; near-term regulatory catalyst.
Companies Mentioned
- Capricor Therapeutics, Inc. (CAPR): Lead candidate Deramiocel (CAP-1002) in late-stage development for DMD; near-term regulatory catalysts.
- U.S. Food and Drug Administration (FDA): Regulatory body reviewing the BLA; advisory committee decision could drive stock moves.
Corporate Developments
Category: Corporate Developments. The article centers on regulatory milestones and evidence supporting Deramiocel's approval pathway, a core corporate catalyst for CAPR.